{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:34Z","timestamp":1792207594536,"version":"4.4.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Using tissue whole exome sequencing (WES) and circulating tumor cell\u2013free DNA (ctDNA), this Australasian Leukaemia &amp; Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response and resistance of marginal zone lymphoma (MZL) to zanubrutinib for patients treated in the MAGNOLIA clinical trial. WES was performed on baseline tumor samples obtained from 18 patients. For 7 patients, ctDNA sequence was interrogated using a bespoke hybrid-capture next-generation sequencing assay for 48 targeted genes. Somatic mutations were correlated with objective response data and survival analysis using Fisher exact test and Kaplan-Meier (log-rank) method, respectively. Baseline WES identified mutations in 33 of 48 (69%) prioritized genes. NF-\u03baB, NOTCH, or B-cell receptor (BCR) pathway genes were implicated in samples from 16 of 18 patients (89%). KMT2D mutations (n\u00a0= 11) were most common, followed by FAT1 (n\u00a0= 9), NOTCH1, NOTCH2, TNFAIP3 (n\u00a0= 5), and MYD88 (n\u00a0= 4) mutations. MYD88 or TNFAIP3 mutations correlated with improved progression-free survival (PFS). KMT2D mutations trended to worse PFS. Acquired resistance mutations PLCG2 (R665W\/R742P) and BTK (C481Y\/C481F) were detected in 2 patients whose disease progressed. A BTK E41K noncatalytic activating mutation was identified before treatment in 1 patient who was zanubrutinib-refractory. MYD88, TNFAIP3, and KMT2D mutations correlate with PFS in patients with relapsed\/refractory MZL treated with zanubrutinib. Detection of acquired BTK and PLCG2 mutations in ctDNA while on therapy is feasible and may herald clinical disease progression. This trial was registered at https:\/\/anzctr.org.au\/ as #ACTRN12619000024145.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009412","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T16:04:15Z","timestamp":1679501055000},"page":"3531-3539","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-4481","authenticated-orcid":false,"given":"Maciej","family":"Tatarczuch","sequence":"first","affiliation":[{"name":"1Monash Hematology, Monash Health, Melbourne, VIC, Australia"},{"name":"2Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Monash University, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-8133","authenticated-orcid":false,"given":"Mark","family":"Waltham","sequence":"additional","affiliation":[{"name":"1Monash Hematology, Monash Health, Melbourne, VIC, Australia"},{"name":"2Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Monash University, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-6488","authenticated-orcid":false,"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"1Monash Hematology, Monash Health, Melbourne, VIC, Australia"},{"name":"2Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Monash University, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9535-9291","authenticated-orcid":false,"given":"Galina","family":"Polekhina","sequence":"additional","affiliation":[{"name":"3School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"3School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia"},{"name":"4Eastern Health, Melbourne, VIC, Australia"},{"name":"5Olivia Newton John Cancer Research Institute at Austin Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir-Jing","family":"Ho","sequence":"additional","affiliation":[{"name":"6St George Hospital, Sydney, NSW, Australia"},{"name":"7St George & Sutherland Clinical School, University of NSW, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Concord Repatriation General Hospital, Sydney, NSW, Australia"},{"name":"9Concord Clinical School, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Brasacchio","sequence":"additional","affiliation":[{"name":"1Monash Hematology, Monash Health, Melbourne, VIC, Australia"},{"name":"2Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Monash University, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melannie","family":"Co","sequence":"additional","affiliation":[{"name":"10BeiGene Co Ltd, USA Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Li","sequence":"additional","affiliation":[{"name":"10BeiGene Co Ltd, USA Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"10BeiGene Co Ltd, USA Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dunne","sequence":"additional","affiliation":[{"name":"11Australasian Leukaemia & Lymphoma Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen S.","family":"Opat","sequence":"additional","affiliation":[{"name":"1Monash Hematology, Monash Health, Melbourne, VIC, Australia"},{"name":"2Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Monash University, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-0682","authenticated-orcid":false,"given":"Gareth P.","family":"Gregory","sequence":"additional","affiliation":[{"name":"1Monash Hematology, Monash Health, Melbourne, VIC, Australia"},{"name":"2Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Monash University, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"issue":"3","key":"2023072114300002900_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"2023072114300002900_bib29","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2023072114300002900_bib3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"2023072114300002900_bib4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2023072114300002900_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/modpathol.2011.213","article-title":"Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities","volume":"25","author":"Braggio","year":"2012","journal-title":"Mod Pathol"},{"key":"2023072114300002900_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-46906-1","article-title":"Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma","volume":"9","author":"Jaramillo Oquendo","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"2023072114300002900_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of Diffuse Large B cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"12","key":"2023072114300002900_bib8","doi-asserted-by":"crossref","first-page":"e127566","DOI":"10.1172\/jci.insight.127566","article-title":"Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity","volume":"4","author":"Wang","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"2023072114300002900_bib9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/hematology.2020000157","article-title":"How do we sequence therapy for marginal zone lymphomas?","volume":"2020","author":"Broccoli","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"2023072114300002900_bib10","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"2023072114300002900_bib11","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023072114300002900_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ajhg.2012.08.006","article-title":"A\u00a0hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency","volume":"91","author":"Zhou","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"Suppl 1","key":"2023072114300002900_bib13","article-title":"BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023072114300002900_bib14","first-page":"445","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Zhang","year":"2015","journal-title":"Br\u00a0J\u00a0Haematol"},{"issue":"894","key":"2023072114300002900_bib15","first-page":"1","article-title":"Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents","volume":"10","author":"Sedlarikova","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"2023072114300002900_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/bloodadvances.2018029058","article-title":"Resistance mechanism for ibrutinib in marginal zone lymphoma","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv"},{"key":"2023072114300002900_bib17","doi-asserted-by":"crossref","first-page":"116358","DOI":"10.1016\/j.bmc.2021.116358","article-title":"Progress in the development of small molecular inhibitors of the Bruton\u2019s tyrosine kinase (BTK) as a promising cancer therapy","volume":"47","author":"Liu","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"2023072114300002900_bib18","volume-title":"Zanubrutinib (BGB-3111) Investigator\u2019s Brochure","author":"Beigene Ltd","year":"2022"},{"issue":"23","key":"2023072114300002900_bib19","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023072114300002900_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A\u00a0phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"issue":"21","key":"2023072114300002900_bib21","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","article-title":"Variant review with the integrative genomics viewer","volume":"77","author":"Robinson","year":"2017","journal-title":"Cancer Res"},{"key":"2023072114300002900_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/CCI.19.00132","article-title":"Integrated informatics analysis of cancer-related variants","volume":"4","author":"Pagel","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"19","key":"2023072114300002900_bib23","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","article-title":"GenVisR: genomic visualizations in R","volume":"32","author":"Skidmore","year":"2016","journal-title":"Bioinformatics"},{"issue":"5","key":"2023072114300002900_bib24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/modpathol.2011.213","article-title":"Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities","volume":"25","author":"Braggio","year":"2012","journal-title":"Modern Pathology"},{"issue":"Suppl 1","key":"2023072114300002900_bib25","article-title":"Clinical relevance of NOTCH1 mutations in ibrutinib-treated chronic lymphocytic leukemia (CLL)","volume":"132","author":"Del Poeta","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023072114300002900_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"10","key":"2023072114300002900_bib26","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2007-09-115170","article-title":"Targeting NF-\u03baB in Waldenstrom macroglobulinemia","volume":"111","author":"Leleu","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2023072114300002900_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/sj.icb.7100095","article-title":"Structure, function and regulation of the Toll\/IL-1 receptor adaptor proteins","volume":"85","author":"Watters","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"2023072114300002900_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620721989586","article-title":"Current and novel BTK inhibitors in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"12","author":"Ntanasis-Stathopoulos","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"18","key":"2023072114300002900_bib30","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A\u00a0randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"23","key":"2023072114300002900_bib31","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2023072114300002900_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2009.05.007","article-title":"The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology","volume":"30","author":"Vereecke","year":"2009","journal-title":"Trends Immunol"},{"issue":"10","key":"2023072114300002900_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-018-0130-3","article-title":"Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma","volume":"8","author":"Wenzl","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"2023072114300002900_bib34","first-page":"1190","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat\u00a0Med"},{"issue":"10","key":"2023072114300002900_bib35","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"issue":"6","key":"2023072114300002900_bib36","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3892\/ijo.2012.1669","article-title":"Function and cancer genomics of FAT family genes (review)","volume":"41","author":"Katoh","year":"2012","journal-title":"Int J Oncol"},{"issue":"5","key":"2023072114300002900_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/1074-7613(95)90026-8","article-title":"Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain","volume":"2","author":"Li","year":"1995","journal-title":"Immunity"},{"issue":"2","key":"2023072114300002900_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/bloodadvances.2021006211","article-title":"Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2023072114300002900_bib39","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2023072114300002900_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"2","key":"2023072114300002900_bib41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2023072114300002900_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2023072114300002900_bib43","article-title":"Determinants of circulating tumor dna levels across lymphoma histologic subtypes","volume":"130","author":"Schroers-Martin","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"2023072114300002900_bib44","article-title":"Assessment of cell-free dna (cfdna) in 221 patients with lymphoproliferative malignancies at diagnosis and during follow-up","volume":"134","author":"Andrade-Campos","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3531\/2065164\/blooda_adv-2022-009412-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3531\/2065164\/blooda_adv-2022-009412-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T14:35:04Z","timestamp":1689950104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3531\/495026\/Molecular-associations-of-response-to-the-new"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":44,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009412","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}